Project Grant R21AG097887
- Federal Project Grant Award Summary Mayo Clinic received a $3.75 million Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective May 15, 2025, with completion targeted for April 30, 2030. The award funds a five-year research initiative examining the relationship between premenopausal bilateral oophorectomy (PBO) and biomarkers associated with Alzheimer's disease and cerebrovascular disease. The research will enroll 400 women (200...
- Federal Project Grant Award Summary Mayo Clinic received a $441,100 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) for the period July 1, 2025 through June 30, 2027. The grant supports research on digital detection of handwriting impairments in patients with atypical Alzheimer's disease and frontotemporal lobar degeneration (FTLD). The project will develop and validate digital tools and methods to collect, analyze, and characterize...
- Federal Project Grant Award Summary Mayo Clinic received a $322,800 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025 through April 30, 2028. The award supports a randomized, placebo-controlled clinical trial investigating the effects of long-acting glucagon-like peptide-1 (GLP-1) receptor agonist and dual incretin (GLP-1 and...
- Federal Project Grant Award Summary Mayo Clinic received a $660,157 Project Grant award from the National Institute on Aging (Aging Research program, CFDA 93.866) effective February 1, 2026, through January 31, 2031. The award funds research investigating the role of BRD4 (Bromodomain and Extraterminal Domain protein 4) in enhancing the preservation quality of donor hearts from older individuals. The research addresses a critical clinical need: while heart transplantation remains the standard...
- Federal Project Grant Award Summary The University of Cincinnati received a $324,000 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective February 15, 2026, through January 31, 2028. This research initiative will investigate the effectiveness and safety of glucagon-like peptide-1 (GLP-1) agonists—medications originally developed for type 2 diabetes—as a preventive intervention for Alzheimer's disease progression in patients with mild...
- Federal Project Grant Award Summary Mayo Clinic received a $3.38 million Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded on September 15, 2025, with a completion date of September 14, 2029. The award supports research to advance women's care in Alzheimer's disease and other dementias through systematic analysis of electronic health records (EHRs). The project addresses a critical gap in precision medicine by examining women-specific health...
- Federal Project Grant Award Summary Mayo Clinic received a $441,100 project grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective August 1, 2025, through July 31, 2027. The award funds a multiomic analysis research initiative investigating the downstream molecular effects of telomere length across individual chromosome arms in healthy human cells. The project develops and applies TeloGator, a novel bioinformatics approach utilizing long-read...
- Federal Project Grant Award Summary Mayo Clinic Arizona has been awarded $420,000 in project grant funding from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 15, 2025, through August 31, 2027. The award funds a longitudinal research study examining quality of life (QOL) and patient priorities among older adults with indolent non-Hodgkin lymphoma (INHL). The study will leverage an existing lymphoma cohort and direct patient narratives to...
- Federal Grant Award Summary Rush University Medical Center received a $431,750 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective February 15, 2026, with a completion date of January 31, 2028. The grant supports a comprehensive pharmacoepidemiologic study investigating the association between proton pump inhibitor (PPI) use and Alzheimer's disease and related dementias (ADRD) risk. The research utilizes four ongoing U.S.-based...
- Federal Grant Award Summary Mayo Clinic received a $377,273 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded September 15, 2025, with completion targeted for August 31, 2027. The grant funds the development of automated data abstraction methods leveraging large language models (LLMs) to improve the accuracy and efficiency of medical registry curation,...
Mayo Clinic received a $443,850 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded March 15, 2026, with completion targeted for February 29, 2028. This research initiative will deliver a comprehensive epidemiological study examining the real-world safety and efficacy of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications in older adults aged 60 years and above. Utilizing linked electronic health records (EHR) from the Rochester Epidemiology Project research infrastructure, the project will analyze a population-based cohort of 26,442 persons in the upper Midwest to assess age-related differences in GLP-1 RA response and outcomes. The deliverables from this project will include evidence-based findings on three critical research aims: (1) comparative analysis of prescription duration, medication changes, and weight loss outcomes between older and middle-aged adults; (2) assessment of medication discontinuation rates and adverse side effects across age groups; and (3) risk stratification for serious health complications including pancreatitis, bowel obstruction, interstitial nephritis, falls, fractures, and frailty. These research outputs will address a critical knowledge gap regarding the translation of GLP-1 RA efficacy from controlled clinical trial settings to general practice, providing essential safety and effectiveness data to inform clinical decision-making as these medications are increasingly prescribed to the aging Medicare population.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $443.9k | 3/13/26 |